The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells

被引:63
|
作者
Oguri, T [1 ]
Achiwa, H [1 ]
Bessho, Y [1 ]
Muramatsu, H [1 ]
Maeda, H [1 ]
Niimi, T [1 ]
Sato, S [1 ]
Ueda, R [1 ]
机构
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Internal Med & Mol Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan
关键词
non-small cell lung cancer; 5-fluorouracil; thymidylate synthase; dihydropyrimidine dehydrogenase; thymidine phosphorylases; orotate phosphoribosyl-transferase;
D O I
10.1016/j.lungcan.2005.05.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The expressions of thymidylate synthase (TS) and intracellular metabolic enzymes have been reported to be associated with the sensitivity and/or resistance to 5-fluorouracil (5-FU). However, since the role of these enzymes in the mechanism of resistance to 5-FU has not been fully examined in lung cancer, in the present study we measured the expression levels of TS, dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), and orotate phosphoribosyltransferase (OPRT) genes in lung cancer cell lines by real-time PCR, and the sensitivity to 5-FU using the MTS assay. The expression of DPD was significantly correlated with the concentration of 5-FU for 50% cell survival in 15 non-small-cell lung cancer (NSCLC) cell lines (p < 0.05), but the expressions of TS, TP, and OPRT were not. Treatment with 5-chloro-2,4-dihydroxypyridine, an inhibitor of DPD, altered the sensitivity to 5-FU in DPD-expressing RERF-LC-MT cells, indicating that modulation of DPD activity could increase the 5-FU sensitivity in lung cancer. In contrast, TS expression was dramatically higher in a 5-FU-resistant small-cell lung cancer cell line than in the parent cell line, whereas the expressions of DPD, TP, and OPRT genes were not markedly different. In order to examine the effect of other cytotoxic agents on TS and DPD expression, we compared the expressions of both genes between cisplatin-, paclitaxel-, gemcitabine-, or 7-ethyl-10-hydroxycamptothecin-resistant lung cancer cells and their respective parent cells, but found no differences between any pair of resistant subline and the corresponding parent cell line. Our results indicate that degradation of 5-FU due to DPD is an important determinant in 5-FU sensitivity, while induction of TS contributes to acquired resistance against 5-FU in lung cancer. Therefore, the expression levels of TS and DPD genes may be useful indicators of 5-FU activity in lung cancer. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:345 / 351
页数:7
相关论文
共 50 条
  • [41] 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer
    Inada, T
    Ogata, Y
    Kubota, T
    Tomikawa, M
    Yamamoto, S
    Andoh, J
    Ozawa, I
    Hishinuma, S
    Shimizu, H
    Kotake, K
    ANTICANCER RESEARCH, 2000, 20 (04) : 2457 - 2462
  • [42] The effect of dihydropyrimidine dehydrogenase (DPD) activity and germline thymidylate synthase (TS) gene polymorphisms on the survival of colorectal cancer patients treated by adjuvant 5-fluorouracil
    Kralovanszky, J.
    Budai, B.
    Pandi, E.
    Hitre, E.
    Adleff, V.
    Katona, C.
    Reti, A.
    Komlosi, V.
    Orosz, Z.
    Lang, I.
    EJC SUPPLEMENTS, 2005, 3 (02): : 187 - 187
  • [43] Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase
    Milczarek, Magdalena
    Rossowska, Joanna
    Klopotowska, Dagmara
    Stachowicz, Martyna
    Kutner, Andrzej
    Wietrzyk, Joanna
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2019, 190 : 139 - 151
  • [44] INVITRO AND INVIVO INHIBITION OF THYMIDYLATE SYNTHASE OF HUMAN-COLON CANCER BY 5-FLUOROURACIL
    PETERS, GJ
    LAURENSSE, EJ
    VANGROENINGEN, CJ
    MEIJER, S
    PINEDO, HM
    PEDIATRIC RESEARCH, 1988, 24 (01) : 130 - 130
  • [45] Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients
    Katona, C
    Kralovanszky, J
    Rosta, A
    Pandi, E
    Fonyad, G
    Toth, K
    Jeney, A
    ONCOLOGY, 1998, 55 (05) : 468 - 474
  • [46] PREDICTION OF SEVERE 5-FLUOROURACIL TOXICITY IN GASTROINTESTINAL CANCER CHEMOTHERAPY: ROLE OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY
    Loganayagam, A.
    Fairbanks, L.
    Arenas-Hernandez, M.
    Ross, P.
    Marinaki, T.
    Sanderson, J. D.
    GUT, 2009, 58 : A83 - A84
  • [47] MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer
    Sun, Z.
    Zhou, N.
    Han, Q.
    Zhao, L.
    Bai, C.
    Chen, Y.
    Zhou, J.
    Zhao, R. C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (11): : 876 - 883
  • [48] Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma
    Morine, Yuji
    Shimada, Mitsuo
    Utsunomiya, Tohru
    Imura, Satoru
    Ikemoto, Tetsuya
    Hanaka, Jun
    Kanamoto, Mami
    Kurita, Nobuhiro
    Miyake, Hidenori
    SURGERY TODAY, 2012, 42 (02) : 135 - 140
  • [49] Dihydropyrimidine Dehydrogenase-Mediated Resistance to 5-Fluorouracil: Mechanistic Investigation and Solution
    Verma, Himanshu
    Narendra, Gera
    Raju, Baddipadige
    Singh, Pankaj Kumar
    Silakari, Om
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2022, : 1017 - 1033
  • [50] Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer - in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase
    Inoue, K
    Takao, M
    Watanabe, F
    Tarukawa, T
    Shimamoto, A
    Kaneda, M
    Sakai, T
    Fukushima, M
    Shimpo, H
    Yada, I
    LUNG CANCER, 2005, 49 (01) : 47 - 54